Elastosis perforans serpiginosa (EPS) is a recognised form of acquired perforating dermatosis. When EPS arises in a patient receiving D-penicillamine and a causal relationship is strongly suspected, a specific clinical approach applies.
Elastosis perforans serpiginosa developing during D-penicillamine treatment — a drug-associated presentation of acquired perforating dermatosis in which D-penicillamine is strongly suspected as the causative agent.
When a causal link between D-penicillamine and EPS is strongly suspected, management centres on addressing the role of the suspected causative drug — the full protocol details the recommended clinical steps.
DOI: 10.1111/1346-8138.15647
In cases in which elastosis perforans serpiginosa develops during the use of D-penicillamine and a causal relationship is strongly suspected, we suggest discontinuing D-penicillamine and consider changing to another drug.
View source ↗